# Codex Conference Review: medication-component-review-20260909

Date: 2026-09-09

## Verdict

Revise. Only isolated experiment authorized; no formal ingestion acceptance.

## Boundary Compliance

Actual ZCode/zcode/GLM-5.3:max, fresh session sess_3a8e0968-ac42-4d50-aa58-c63438929c90, no fallback. Same model family as executor/productGLM, different variant and context; reduced model independence acknowledged. No file edits or new product inference by reviewer.

## Participant Outputs Reviewed

runs/conference/medication-component-review-20260909/evidence_single_object.md, round2.md and actual stdout receipts. First33 and then42 focused tests were executed; reviewer did not view original images.

## Conference Panel Review

Accept F1 interval parsing, F2 impossible-date unresolved, F3 possible missing time hint, F6 original context preservation. Owner implemented v3 with42 focused tests. Do not implement heuristic two-conflict count as proof of wrong pairing, or duplicate-drug-name as clinical truth; those require broader event context. Do not strengthen raw text equality into accepted fact.

## Main-Venue Codex Review

Correct reviewer counts: actual v2 is15 pairs/30 responses, not18 pairs. Its claim that information loss occurs only upstream is contradicted by F3: date is present in input excerpt and omitted by the component model. Original cross-page name fragments are page-boundary evidence, not automatically upstream mistakes. These report errors were not adopted.

## Codex Independent Verification

Owner viewed SAR pages1/4/5 and D001 receipt originals. V2 original requests and responses preserved; one adverse same-drug/different-date+dose pair retains both conflicts. V3 targeted6/6 responses now preserve the previously omitted year, but time roles still differ and formulation wording still conflicts. No full-subject clinical or UI acceptance. V3 D001 receipt counterexample runs separately to test product-specification versus dose/expiry versus treatment time.

## Final Decision

No automatic product integration. Round2 confirms v3 changes with remaining source-role limitations. Owner accepted the optional interval search strengthening and added prefix/suffix counterexamples (44 isolated tests). No mandatory model bbox adopted: product visual locators already deliberately discard unverified model coordinates. Continue bounded source-preserving experiments and capture remaining clinical scope limitations; require explicit user approval only after decisive evaluation, not now.
